Sudhir Vrundavandas Valia, who is executive director with Sun Pharma,
has picked up 1.41% stake in Ranbaxy Laboratories. The stake was bought
by Mumbai-based Silverstreet Developers Llp in which Valia is partner.
Approximately 59,67,542 valued at a little over Rs 247.65 crore (average share price at Rs 415 for the December quarter) are being held by Silverstreet according to shareholding pattern released by Ranbaxy for the quarter ended December 2013.
Ranjit Kapadia, senior vice president - Pharma, Centrum Broking Ltd, said, "Sudhir Valia’s move seems to be that of a strategic investor in the company from long-term perspective. From Sun Pharma point of view there is no change, as the shares have been acquired in his personal capacity."
In another development, Ranbaxy Laboratories has inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis. The product will be introduced in India and other emerging markets, Ranbaxy said in a statement.
Kapadia is of the opinion that the licencing agreement will help Epirus market its biosimilar in India through a large field force of Ranbaxy without setting up own field force and distribution channel. "However, the molecule has recently completed Phase 3 studies and it would take 12-18 months to get regulatory approval and commercialise the product in India," said Kapadia.
Zydus Cadila gets US nod for two drugs
Drug firm Zydus Cadila has received approval from the US Food and Drug Administration (USFDA) to market Sirolimus tablets 0.5 mg with 180 days of marketing exclusivity Sirolimus. As per the IMS data in 2013, the sales of Sirolimus 0.5 mg is estimated at USD 11.7 million and the total market for Sirolimus stood at around USD 203.8 million.
The Ahmedabad-based firm has also received USFDA approval to market Duloxetine delayed release capsules in different strengths of 20 mg, 30 mg and 60 mg. The sales for Duloxetine was estimated at USD 5.5 billion in 2013.
While Sirolimus tablets are immunosuppressant drugs used to prevent rejection in organ transplantation, Duloxetine delayed release capsules fall in the anti-depressants segment.
Approximately 59,67,542 valued at a little over Rs 247.65 crore (average share price at Rs 415 for the December quarter) are being held by Silverstreet according to shareholding pattern released by Ranbaxy for the quarter ended December 2013.
Ranjit Kapadia, senior vice president - Pharma, Centrum Broking Ltd, said, "Sudhir Valia’s move seems to be that of a strategic investor in the company from long-term perspective. From Sun Pharma point of view there is no change, as the shares have been acquired in his personal capacity."
In another development, Ranbaxy Laboratories has inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis. The product will be introduced in India and other emerging markets, Ranbaxy said in a statement.
Kapadia is of the opinion that the licencing agreement will help Epirus market its biosimilar in India through a large field force of Ranbaxy without setting up own field force and distribution channel. "However, the molecule has recently completed Phase 3 studies and it would take 12-18 months to get regulatory approval and commercialise the product in India," said Kapadia.
Zydus Cadila gets US nod for two drugs
Drug firm Zydus Cadila has received approval from the US Food and Drug Administration (USFDA) to market Sirolimus tablets 0.5 mg with 180 days of marketing exclusivity Sirolimus. As per the IMS data in 2013, the sales of Sirolimus 0.5 mg is estimated at USD 11.7 million and the total market for Sirolimus stood at around USD 203.8 million.
The Ahmedabad-based firm has also received USFDA approval to market Duloxetine delayed release capsules in different strengths of 20 mg, 30 mg and 60 mg. The sales for Duloxetine was estimated at USD 5.5 billion in 2013.
While Sirolimus tablets are immunosuppressant drugs used to prevent rejection in organ transplantation, Duloxetine delayed release capsules fall in the anti-depressants segment.
No comments:
Post a Comment